Novel Coronavirus (SARS-CoV-2): Molecular Biology, Pathogenesis, Pathobiology and Advances in Treatment of COVID-19 Patients – An Update
December 2020
in “
Journal of Experimental Biology and Agricultural Sciences
”
Studysummary This article reviews the structure, genomic organization, and pathogenesis of SARS-CoV-2 and discusses current efforts in prevention and treatments for COVID-19 without reporting new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document provided an update on the novel coronavirus (SARS-CoV-2), detailing its molecular biology, pathogenesis, and pathobiology, as well as advances in treatment for COVID-19 patients as of late 2020. SARS-CoV-2, responsible for a global pandemic, had caused nearly 1.4 million deaths from over 59 million confirmed cases by November 2020. The virus was classified under the Betacoronavirus genus and shared significant genomic similarities with bat coronavirus RaTG13, suggesting a bat origin. The virus's spike protein interacted with the human ACE2 receptor, facilitating infection. At the time, no vaccines or specific drugs were available, prompting efforts in early diagnosis, prevention, and control measures, including social distancing and boosting immunity through nutrition and exercise, to combat the pandemic. The article summarized the structure, genomic organization, and ongoing research efforts to treat COVID-19.
